Piper Sandler Trims Sight Sciences (NASDAQ:SGHT) Target Price to $17.00

Sight Sciences (NASDAQ:SGHTGet Rating) had its price objective lowered by Piper Sandler from $23.00 to $17.00 in a research note released on Wednesday, The Fly reports.

Other analysts have also issued research reports about the stock. William Blair assumed coverage on shares of Sight Sciences in a research report on Thursday, February 3rd. They set an outperform rating on the stock. Zacks Investment Research lowered shares of Sight Sciences from a buy rating to a hold rating in a report on Thursday, March 10th. Finally, Citigroup cut their price target on shares of Sight Sciences from $39.00 to $35.00 and set a buy rating on the stock in a report on Friday, March 25th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Sight Sciences currently has a consensus rating of Buy and an average target price of $28.40.

NASDAQ SGHT opened at $8.19 on Wednesday. The company has a current ratio of 21.28, a quick ratio of 20.26 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $389.76 million and a price-to-earnings ratio of -2.65. The firm’s 50 day simple moving average is $10.82 and its 200 day simple moving average is $15.88. Sight Sciences has a 1 year low of $6.25 and a 1 year high of $42.57.

Sight Sciences (NASDAQ:SGHTGet Rating) last posted its quarterly earnings results on Thursday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.05. Sight Sciences had a negative net margin of 134.02% and a negative return on equity of 51.67%. On average, equities research analysts forecast that Sight Sciences will post -1.79 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in SGHT. Deutsche Bank AG bought a new position in Sight Sciences during the third quarter worth $162,000. Advisor Group Holdings Inc. bought a new stake in Sight Sciences in the third quarter valued at $45,000. Jennison Associates LLC bought a new stake in Sight Sciences in the third quarter valued at $879,000. BlackRock Inc. bought a new stake in Sight Sciences in the third quarter valued at $13,547,000. Finally, Alliancebernstein L.P. bought a new stake in Sight Sciences in the third quarter valued at $28,324,000. 60.76% of the stock is owned by institutional investors and hedge funds.

About Sight Sciences (Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

See Also

The Fly logo

Analyst Recommendations for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.